SanBio CoTSE:4592 +4.95%22 Current Ratio is 28.99 as of Jan. 2026, which is 390% above its 10-year median of 5.92. GuruFocus rates TSE:4592 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, SanBio Co ranks better than 98.51% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. SanBio Co's current ratio for the quarter that ended in Jan. 2026 was 28.99.
SanBio Co has a current ratio of 28.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for SanBio Co's Current Ratio or its related term are showing as below:
TSE:4592'
s Current Ratio Range Over the Past 10 Years
Min: 2.41 Med: 5.92 Max: 53
Current: 53
During the past 13 years, SanBio Co's highest Current Ratio was 53.00. The lowest was 2.41. And the median was 5.92.
TSE:4592's Current Ratio is ranked better than 98.51% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs TSE:4592: 53.00
SanBio Co (TSE:4592) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
SanBio Co Current Ratio Related Terms
SanBio Co Current Ratio Historical Data
* Premium members only.
The historical data trend for SanBio Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4592 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, SanBio Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SanBio Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SanBio Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where SanBio Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SanBio Co (TSE:4592) has a Current Ratio of 28.99 as of Jan. 2026. This is 390% above median its historical median of 5.92. Over the past decade, SanBio Co's Current Ratio has ranged from 2.41 to 53.00. According to the industry distribution chart, SanBio Co ranks #21 out of 1409 companies in the Biotechnology industry, placing it in the top 1.5%.
Is SanBio Co's Current Ratio too high?
SanBio Co's current Current Ratio of 28.99 is 390% above median its 10-year median of 5.92. Over the past 10 years, this metric has ranged from a low of 2.41 to a high of 53.00. The Biotechnology industry median Current Ratio is 3.89. SanBio Co's value of 28.99 is 645.2% above this industry median. Based on the distribution chart, SanBio Co ranks #21 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SanBio Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SanBio Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SanBio Co ranks #21 out of 1409 companies for Current Ratio. This places SanBio Co in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. SanBio Co's value of 28.99 is 645.2% above this benchmark. Historically, SanBio Co's own Current Ratio has ranged from 2.41 to 53.00 over the past decade. While the company's 10-year median is 5.92 vs. the industry median of 3.89, SanBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SanBio Co's current Current Ratio of 28.99 is 645.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SanBio Co's current Current Ratio is 28.99, which is 390% above median its own 10-year median of 5.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SanBio Co stock overvalued right now?
SanBio Co (TSE:4592) has a current Current Ratio of 28.99. The current Current Ratio is 28.99, which is 390% above median its 10-year median of 5.92 and 645.2% above the Biotechnology industry median of 3.89. SanBio Co's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For SanBio Co (TSE:4592), the current Current Ratio is 28.99 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
22GF Score
Get the complete analysis for TSE:4592
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4592 has been successfully added to your 
